Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916
about
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsThe role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UKThe combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory studyCirculating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.Update on options for treatment of metastatic castration-resistant prostate cancerEvolving role of bone biomarkers in castration-resistant prostate cancer.Changes of protein expression in prostate cancer having lost its androgen sensitivity.Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 studyCOOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER.Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit.Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer.Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancerDual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3MET and VEGF: synergistic targets in castration-resistant prostate cancerProspective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patientsMathematical modeling of prostate cancer progression in response to androgen ablation therapy.Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trialsCastration-resistant prostate cancer: systemic therapy in 2012Predictors of Time to Metastasis in Castration-resistant Prostate Cancer.Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.An update on androgen deprivation therapy for prostate cancer.The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC).Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall SurvivalCurrent approaches, challenges and future directions for monitoring treatment response in prostate cancer.Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CTPredicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer.Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).Testosterone in prostate cancer: the Bethesda consensus.MicroRNAs as putative mediators of treatment response in prostate cancer.Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist?New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.The utility of prostate-specific antigen in the management of advanced prostate cancer.Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.Degarelix: a review of its use in patients with prostate cancer.PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials.Drug design strategies for the treatment of prostate cancer.'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer.
P2860
Q26750672-BB3DC1CA-9A72-4BAF-826A-0650F9ED5C40Q28072710-F83CAA7B-CCDD-447B-8B83-CE16515B2F5DQ28388750-0448A8BC-12AD-4309-A2F2-C7E6260FABDDQ30574916-BBF73EED-5F82-4D51-8CFE-E638EEDAD7F3Q33956051-458564D7-2CBF-4E7F-95BC-E9F089573832Q34023877-838E3179-0B60-4F6F-9851-ADC721B724D8Q34043941-394861AE-0F1F-4A70-974D-F4E549B1BFEBQ34179268-F3BB34BA-2E39-4D3C-831F-7B20981277BFQ34309132-C6748905-DC1C-4390-962B-81433DDFB175Q34417941-13CA7DEB-A62D-4AA3-AD82-39DBF6CB3CBAQ34536729-399675A2-7B3E-4481-8528-F93F36B722B9Q34636636-356C4E45-8EE3-45F2-88F0-74C312C89F4CQ35158676-12F5EF68-87C7-4AE7-BCBA-BD0416CC73C4Q35269318-6D304A5E-29E5-4594-8FC6-0F979D106F25Q35575488-2011C476-56A1-4340-9A90-67FAE1E63B19Q35602593-0CA80295-07D5-4748-B725-5682D7EC6B9CQ35621205-8660B6FF-F05D-463E-A947-ABB05452AB1EQ35656240-53EF9E27-2D26-4B12-BDFC-FF5FD1A45390Q35865011-E95BE8ED-6838-4C36-B403-1A84EAD2681DQ36056137-E33C3984-5731-4808-AEA0-FD72F074AAD9Q36243296-F5DEE7FE-1D53-4FDA-888D-1BA880EABF00Q36289952-D8558423-917F-475A-96B8-D86DF8735761Q36353287-D975DC6B-75C0-4293-95C1-DB20E5842DD9Q36746831-DFC3CBD1-993B-4C26-9AC9-0E68E477440BQ36909750-99BD9249-FDD0-49A9-86A6-45247853999DQ37435181-C925F782-A652-4E97-AC6F-51C48B086C3AQ37496697-B78FAA39-80C0-4F38-9484-28C2D3136312Q37613206-B122F37F-C312-46E9-B82B-F52F33012D7AQ37672267-F2A48FD0-24D0-4D8D-9D7E-8408746F121FQ37950459-286038C1-A56B-494B-85DC-12F07E0DC9F0Q37963010-D17D1CDC-E6D1-46B8-8410-830AF8B892F8Q38011943-52A5640D-48B0-4407-8E7F-47958F2B3D3DQ38023123-16CB8562-980C-43E5-8CFC-452294821B8AQ38023124-AE0E8C60-61B1-4939-A607-F26E8ADA4364Q38119260-D98500C2-7CDF-4A70-B66D-5E9130585F0CQ38168261-3F784AC3-2A05-4264-92CC-215960418EB2Q38206404-3D8DBD5B-BE37-4CE8-AC5D-F34181C18654Q38246587-95787A23-2BB5-4760-85CD-0F6334C32D70Q38264673-5799DE6D-87BD-48B3-BC6A-D65651ACF14BQ38366829-4235EE22-8E6B-4931-B607-D3E756271094
P2860
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Prostate-specific antigen prog ...... ntergroup Study 0162) and 9916
@ast
Prostate-specific antigen prog ...... ntergroup Study 0162) and 9916
@en
type
label
Prostate-specific antigen prog ...... ntergroup Study 0162) and 9916
@ast
Prostate-specific antigen prog ...... ntergroup Study 0162) and 9916
@en
prefLabel
Prostate-specific antigen prog ...... ntergroup Study 0162) and 9916
@ast
Prostate-specific antigen prog ...... ntergroup Study 0162) and 9916
@en
P2093
P2860
P356
P1476
Prostate-specific antigen prog ...... ntergroup Study 0162) and 9916
@en
P2093
Atif M Akdas
Bryan Goldman
Bryan J Donnelly
Cathy Tangen
Celestia S Higano
Daniel P Petrylak
E David Crawford
Eric J Small
Maha Hussain
Patrick A Burch
P2860
P304
P356
10.1200/JCO.2008.19.9810
P407
P577
2009-04-20T00:00:00Z